- CRS provides R&D-grade production of plasmid DNA (pDNA), various RNA modalities (mRNA, circular RNA, saRNA) and lipid nanoparticles (LNPs) for preclinical studies.
- Services include plasmid and RNA construct design and optimization (UTR, poly(A), cap), lipid library screening, LNP formulation, functional assays and analytical support.
- CRS is based at the WACKER Biotechnology Center in Munich and offers scale-up and transfer to Wacker Biotech’s GMP network in Halle, Jena, Amsterdam and San Diego for clinical supply.
- Early customers include SRTD Biotech, which is developing seRNA-based therapies using fusogenic LNPs for organ-specific targeting.
Service offering
WACKER's Contract Research Services provide R&D-grade production of plasmid DNA (pDNA), RNA modalities (mRNA, circular RNA, self-amplifying RNA) and lipid nanoparticles (LNPs) for preclinical in vitro and in vivo studies, together with construct design, RNA engineering and optimization (UTR, poly(A), cap), lipid library screening, LNP formulation, functional assays and analytical services.
Capabilities and expertise
The Munich-based CRS team operates from the WACKER Biotechnology Center, uses the PLASMITEC platform and a proprietary E. coli strain for pDNA production, and has led more than 100 collaborations with academic and consortia partners, providing experience across RNA modalities relevant to advanced therapeutics and vaccines.
Scale-up and GMP network
CRS combines early-stage R&D support with defined transfer pathways to Wacker Biotech's GMP manufacturing network in Halle, Jena, Amsterdam and San Diego to enable process scale-up and clinical material supply.
Customers and roadmap
Early customers include SRTD Biotech, which develops selectively expressed RNAs (seRNAs) and uses fusogenic LNPs for organ-specific targeting; WACKER intends to extend CRS capabilities beyond nucleic-acid modalities to include protein-based services.
